Form 4: Delcath Systems Director Receives Equity Grant

Director Bridget A. Martell was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Summary

• Director Bridget A. Martell received a grant of 22,500 stock options on May 13, 2026.
• The options have an exercise price of $11.61 per share.
• The grant is subject to the terms of the Issuer's 2020 Omnibus Equity Incentive Plan.
• The options vest at a rate of 1/12th per month, beginning May 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.
• Continued service as a director is required for the full vesting of the options.

Future Outlook

The options expire 10 years from the grant date or two years after the director ceases service, whichever is earlier.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director equity is consistent with standard practices for small-cap biotechnology firms.
• The 10-year expiration term is standard for executive and director stock option plans.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Monthly vesting of options to continue as long as the reporting person remains a director.

Key Dates

Keywords

Delcath Systems, DCTH, Form 4, Insider Trading, Stock Options, Equity Compensation